Impact of inflammatory markers on survival in patients with limited disease small-cell lung cancer undergoing chemoradiotherapy

ISSN
1179-1322
Date Issued
2018
Author(s)
Bernhardt, Denise
Aufderstrasse, Sophie
König, Laila
Adeberg, Sebastian
Bozorgmehr, Farastuk
Christopoulos, Petros
Shafie, Rami A El
Hörner-Rieber, Juliane
Kappes, Jutta
Thomas, Michael
Herth, Felix
Steins, Martin
Debus, Jürgen
DOI
10.2147/CMAR.S180990
Abstract
Systemic inflammation appears to play a role in the progression of numerous solid tumors by promoting tumor proliferation. Our current study aimed to evaluate the role of inflammatory markers in limited disease (LD) small-cell lung cancer (SCLC) patients undergoing thoracic chemoradiotherapy (TCR).